TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TENAX THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.52+0.16 (+11.76%)
Close on Oct 19, 2026
- Market cap
- $77.32M
- P/E (TTM)
- –
- Dividend yield
- –
Tenax Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Market Cap | $56.88M | $164.85M |
| Enterprise Value | -$61.12M | $87.06M |
| PB Ratio | 0.50 | 2.03 |
| P/TBV Ratio | 0.50 | 2.31 |
Income (trailing twelve months)
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Revenue | $0 | $57.94M |
| Operating Income | -$68.61M | -$21.44M |
| Net Income | -$64.86M | -$22.46M |
| EBITDA | -$68.61M | -$16.91M |
| EPS (Diluted) | -$1.48 | -$0.83 |
Returns
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -59.8% | -53.1% |
| Return on Assets (ROA) | -57.0% | -41.0% |
| Return on Capital Employed (ROCE) | -60.4% | -37.8% |
Balance sheet
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $118.00M | $62.42M |
| Net Cash (Debt) | $118.00M | $15.68M |
| Net Cash Per Share | $3.15 | $0.66 |
| Equity (Book Value) | $113.59M | $48.79M |
| Book Value Per Share | $3.04 | $1.36 |
| Tangible Book Value | $113.59M | $23.06M |
| Working Capital | $113.59M | $75.77M |
Financial position
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 15.07 | 3.30 |
| Quick Ratio | 14.62 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$46.03M | -$12.35M |
Efficiency
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.00 | 0.38 |
| Revenue Per Employee | $0 | $398.96K |
| Profits Per Employee | -$4.63M | -$703.34K |
| Employee Count | 14 | 74 |
Dividends and yields
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -114.0% | -22.7% |
Shares
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 37,423,900 | 58,179,650 |
| Shares Change (QoQ) | 31.6% | 0.54% |
| Float | 35,633,200 | 49,173,100 |
| Shares Held by Insiders | 4.79% | 11.6% |
| Shares Held by Institutions | 81.1% | 59.4% |
Scores
| Measure | Tenax Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.13 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Tenax Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.